MAIA Biotechnology stockholders approve increase in authorized common shares to 150M

MAIA Biotechnology, Inc.

Stockholders re-elected Class III directors Jean-Manassé Theagène and Stan V. Smith for three-year terms.
Ratified Grant Thornton LLP as independent auditor for FY2025.
Approved amendment to increase authorized common stock from 70M to 150M shares.
Certificate of Amendment filed on May 22, 2025, effecting the share increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.